Abstract Library

#4670 The efficacy of first-line combination therapy with everolimus plus lanreotide for gastroenteropancreatic neuroendocrine tumour with a poor prognostic factor: Updated and subgroup analysis of the phase III study, STARTER-NET (JCOG1901)

Introduction: Everolimus monotherapy provided a limited median progression-free survival (PFS) for gastroenteropancreatic neuroendocrine tumours (GEP-NETs), there remains a necessity for better therapeutic approaches.

Conference:

Presenting Author:

Authors: Hijioka S, Honma Y, Machida N, Mizuno N, Hamaguchi T,

Keywords: everolimus, lanreotide, PFS, RCT,

#3982 Safety and efficacy of peptide radionuclide therapy (PRRT) with 177Lu-DOTATATE for Japanese patients with neuroendocrine neoplasm (NEN): A single-center retrospective study

Introduction: After the approval of peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in Japan (June 2021), its treatment experience is increasing, but limited data are available in Japanese patients with neuroendocrine neoplasm (NEN).

Conference:

Presenting Author:

Authors: Okamoto K, Hijioka S, Goto Y, Honma Y, Hirano H,

Keywords: PRRT, 177Lu-DOTATATE, Japanese cohort,

#3958 Treatment strategy for pancreatic NETs smaller than 2 cm should be based on the diagnosis of malignancy as well – New treatment strategy for small pancreatic NETs

Introduction: There are still many unclear issues regarding the treatment of non-functioning small (≤20 mm) pancreatic neuroendocrine neoplasms (pNENs).

Conference:

Presenting Author: Hijioka S

Authors: Hijioka S, Yamashige D, Esaki M, Honda G, Masui T,

Keywords: small pancreatic neuroendocrine neoplasm, tumor size, grading, treatment strategy, Japanese cohort,

#2167 Evaluation of Streptozocin-Based Chemotherapeutic Regimens for Advanced Pancreatic Neuroendocrine Tumors: A Multi-Center Clinical Study in Japan

Introduction: Streptozocin (STZ) has been used as a key drug against advanced pancreatic neuroendocrine tumors (pNETs). The standard in many countries is a daily STZ regimen combined with 5-fluorouracil administered once daily for 5 days every 6 weeks. However, in Japan, STZ was only covered by insurance beginning in 2015, and STZ is often used as monotherapy, as either a daily or a weekly regimen. There are few reports on STZ monotherapy for pNETs.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Sakamoto Y, Hijioka S, Shibuya H, Ito T, Imamura M,

Keywords: Streptozocin, pNETs,

#1788 Prospective Observational Study 1 on the Prognosis of Patients with Unresectable Advanced Gastrointestinal and Pancreatic Neuroendocrine Tumors (PROP-UP 1 Study) in Japan

Introduction: No previous observational studies on the prognosis of advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) [pancreatic neuroendocrine neoplasms (PNENs) and gastrointestinal neuroendocrine neoplasms (GI-NENs)] exist in Japan.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Toriyama K, Hijioka S, Komoto I, Kobayashi N, Okusaka T,

Keywords: prop-up, japan, gep-nen,